About Trillium Therapeutics

Our lead program SIRPαFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that allows tumor cells to escape destruction by the immune system.

Trillium is initiating a phase I dose-escalation study of SIRPαFc in patients with advanced lymphoma and other hematological malignancies.


CD47 binds SIRPαFc on the surface of macrophages, and transmits a "do not eat" signal that protects cells from macrophage attack

More >


Email Address: *
First Name:
Mailing Lists

Enter the code shown above.

Powered By Q4 Inc.